PMID- 35599768
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220524
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Electronic)
IS  - 1664-0640 (Linking)
VI  - 13
DP  - 2022
TI  - Using Experience Sampling Methodology Data to Characterize the Substance Use of 
      Youth With or At-Risk of Psychosis.
PG  - 874246
LID - 10.3389/fpsyt.2022.874246 [doi]
LID - 874246
AB  - OBJECTIVES: Psychotic-spectrum disorders emerge during adolescence and early 
      adulthood, which corresponds with the peak period for substance use initiation. 
      Clinical and epidemiological data provide support that substance use is 
      associated with psychotic symptom onset and severity. Experience-sampling 
      methodology (ESM) data may provide additional insight into dynamic associations 
      between substance use and psychotic symptoms. This is one of the first efforts to 
      characterize substance use frequency and dynamic associations with psychotic 
      symptoms and negative affect from ESM data in both clinical high risk (CHR) and 
      early psychosis (EP) individuals. METHODS: Using ESM, 33 individuals, including 
      17 with CHR and 16 EP (age range: 15-24), provided information on substance use, 
      negative affect, and psychotic symptoms 6 times a day across a 21-day data 
      collection window. Psychotic symptoms and negative affect included multi-item 
      variables rated on a seven-point Likert Scale. Participants reported recent 
      substance use for 4 drug classes (nicotine, cannabis, depressants, stimulants) 
      via a yes/no item. Descriptive information included data on substance use 
      frequency, and momentary negative affect and psychotic symptoms. Exploratory 
      analyses included multi-level and person-level dynamic structural equation 
      models, which assessed contemporaneous and lagged associations between substance 
      use and symptoms. RESULTS: Twenty-seven individuals (82%) reported recurrent 
      substance use including stimulants (n = 12, 46%), nicotine (n = 9, 27%), cannabis 
      (n = 6, 18%), and depressants (n = 4, 12%). Individuals with any recurrent 
      substance use indicated usage at 47.7% of answered prompts; stimulants at 23.6%; 
      nicotine at 74.2%; cannabis at 39.1%; and depressants at 20.1%. A multi-level 
      dynamic structural equation model reflected that substance use (any class) was 
      associated with lagged negative affect (beta = -0.02, CI: -0.06, < -0.00) but no 
      significant contemporaneous or lagged associations between substance use and 
      psychotic symptoms. Person-level models suggest potentially meaningful 
      inter-individual variability. CONCLUSIONS: CHR and EP individuals use a range of 
      substances that may both reflect and influence other experiences in daily life 
      experiences. Data reflected moderate to high rates of recurrent substance use 
      with more consistent use within nicotine and cannabis classes. ESM data have the 
      potential to increase our understanding of the dynamic relationships between 
      substance use and symptoms and to inform treatment for individuals in early 
      course psychosis.
CI  - Copyright (c) 2022 Weiss, Bernier, Robbins, Elacqua, Johnson, Powers, 
      Mesholam-Gately and Woodberry.
FAU - Weiss, David M
AU  - Weiss DM
AD  - Maine Medical Center Research Institute, MaineHealth, Portland, ME, United 
      States.
FAU - Bernier, Elizabeth
AU  - Bernier E
AD  - Maine Medical Center Research Institute, MaineHealth, Portland, ME, United 
      States.
FAU - Robbins, Douglas R
AU  - Robbins DR
AD  - Maine Medical Center Research Institute, MaineHealth, Portland, ME, United 
      States.
AD  - Department of Psychiatry, Tufts University School of Medicine, Boston, MA, United 
      States.
FAU - Elacqua, Katherine M
AU  - Elacqua KM
AD  - Maine Medical Center Research Institute, MaineHealth, Portland, ME, United 
      States.
FAU - Johnson, Kelsey A
AU  - Johnson KA
AD  - Massachusetts Mental Health Center Public Psychiatry Division of the Beth Israel 
      Deaconess Medical Center, Boston, MA, United States.
FAU - Powers, Kate
AU  - Powers K
AD  - Maine Medical Center Research Institute, MaineHealth, Portland, ME, United 
      States.
FAU - Mesholam-Gately, Raquelle I
AU  - Mesholam-Gately RI
AD  - Massachusetts Mental Health Center Public Psychiatry Division of the Beth Israel 
      Deaconess Medical Center, Boston, MA, United States.
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, United States.
FAU - Woodberry, Kristen A
AU  - Woodberry KA
AD  - Maine Medical Center Research Institute, MaineHealth, Portland, ME, United 
      States.
AD  - Department of Psychiatry, Tufts University School of Medicine, Boston, MA, United 
      States.
LA  - eng
PT  - Journal Article
DEP - 20220503
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC9116148
OTO - NOTNLM
OT  - dynamic association
OT  - early psychosis
OT  - ecological momentary assessment
OT  - momentary data
OT  - negative affect
OT  - psychotic symptom
OT  - psychotic-spectrum disorders
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/05/24 06:00
MHDA- 2022/05/24 06:01
PMCR- 2022/05/03
CRDT- 2022/05/23 03:43
PHST- 2022/02/11 00:00 [received]
PHST- 2022/04/11 00:00 [accepted]
PHST- 2022/05/23 03:43 [entrez]
PHST- 2022/05/24 06:00 [pubmed]
PHST- 2022/05/24 06:01 [medline]
PHST- 2022/05/03 00:00 [pmc-release]
AID - 10.3389/fpsyt.2022.874246 [doi]
PST - epublish
SO  - Front Psychiatry. 2022 May 3;13:874246. doi: 10.3389/fpsyt.2022.874246. 
      eCollection 2022.